These cells identify a protein complex of butyrophilin 2A1 (BTN2A1) and BTN3A1 which are widely expressed on cell surface activated by phosphoantigens profusely produced by tumor cells (Mamedov et al., 2023[5]), making them promising agents for the advancement of tumor immunotherapy. Here, BTN3A1 is linked to neoplasm.